A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1573-7217

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer ; volume:180 ; number:1 ; day:17 ; month:1 ; year:2020 ; pages:135-146 ; date:2.2020
Breast cancer research and treatment ; 180, Heft 1 (17.1.2020), 135-146, 2.2020

Creator: Masuda, Norikazu
Ohtani, Shoichiro
Takano, Toshimi
Inoue, Kenichi
Suzuki, Eiji
Nakamura, Rikiya
Bando, Hiroko
Ito, Yoshinori
Ishida, Kazushige
Yamanaka, Takashi
Kuroi, Katsumasa
Yasojima, Hiroyuki
Kasai, Hiroi
Takasuka, Tsuyoshi
Sakurai, Takaki
Kataoka, Tatsuki R.
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu

Contributor: SpringerLink (Online service)

DOI: 10.1007/s10549-020-05524-6

URN: urn:nbn:de:101:1-2020051520365176380431

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Masuda, Norikazu
Ohtani, Shoichiro
Takano, Toshimi
Inoue, Kenichi
Suzuki, Eiji
Nakamura, Rikiya
Bando, Hiroko
Ito, Yoshinori
Ishida, Kazushige
Yamanaka, Takashi
Kuroi, Katsumasa
Yasojima, Hiroyuki
Kasai, Hiroi
Takasuka, Tsuyoshi
Sakurai, Takaki
Kataoka, Tatsuki R.
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
SpringerLink (Online service)

Other Objects (12)

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Hochschulschrift

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pertuzumab/Trastuzumab (Mammakarzinom, neoadjuvant) : Nutzenbewertung gemäß § 35a SGB V

Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Einsatz von Pertuzumab und Trastuzumab im Vergleich zu Trastuzumab-Monotherapie beim HER2-positiven Mammakarzinom - eine multizentrische Kohortenstudie

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Pertuzumab/Trastuzumab (Mammakarzinom, adjuvant) : Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung); Dossierbewertung

Related objects

Reset password